Ad-hoc | 15 May 2002 19:32

Eckert & Ziegler AG english

Eckert & Ziegler to Market Prostate Cancer Products in the U.S. Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Eckert & Ziegler to Market Prostate Cancer Products in the U.S. Shareholder Meeting Approves Dividend. Berlin, 15.05.2002. Eckert & Ziegler AG, a manufacturer for radioactive implants for the treatment of prostate cancer, will start to directly market its products in the American market. For this purpose the company will utilize the customer base and sales force of “Alliant Medical Technologies”, which filed for Chapter 7 relief on Wednesday. In the United States approximately 60,000 patients each year chose radioactive implants for the treatment of prostate cancer. The method is significantly more economical than traditional surgical treatment and has lower side effects. Eckert & Ziegler is the leading European manufacturer of radioactive implants for the treatment of prostate cancer and had been barred previously from marketing directly in the U.S. by contractual restrictions. The shareholder meeting of Eckert & Ziegler Strahlen- und Medizintechnik today also approved a dividend of 0.45 EUR. Eckert & Ziegler has 3.25 mm shares and in 2001 reported earnings of about 3.2 mm EUR. The Board of Directors For further information please contact: Eckert & Ziegler AG Karolin Riehle, Investor Relations, Tel. +49 (0) 30 / 94 10 84-138 end of ad-hoc-announcement (c)DGAP 15.05.2002 ——————————————————————————– WKN: 565970; ISIN: DE0005659700; Index: Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 151932 Mai 02